The commission is also in discussions to purchase a joint 500 million doses of 2 other prospective vaccines, officials stated: 1 from Johnson & Johnson, along with a concerted effort between Sanofi and GlaxoSmithKline. All 3 candidates still need to finish closing clinical trials to prove they are safe and effective from COVID-19.
AstraZeneca has also inked an around $1.2 billion agreement to supply the US authorities with 300 million doses of this shot that it has developed with the University of Oxford.
European officials didn't disclose the purchase price of their purchase, but they said the cash will come out of a 2.7 billion euro (approximately $3.2 billion) crisis fund which intends to combat the pandemic.
The Cambridge, UK-based firm has started a vital Phase 3 trial of this vaccine in Brazil and intends to kick off an identical late-stage research from the US this past month.